Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antineoplastic Combined Chemotherapy Protocols | 21 | 2024 | 11736 | 0.840 |
Why?
|
Biliary Tract Neoplasms | 6 | 2023 | 185 | 0.760 |
Why?
|
Cholangiocarcinoma | 6 | 2024 | 552 | 0.750 |
Why?
|
Bile Duct Neoplasms | 6 | 2024 | 605 | 0.740 |
Why?
|
Carcinoma, Hepatocellular | 13 | 2023 | 2291 | 0.740 |
Why?
|
Liver Neoplasms | 15 | 2023 | 4308 | 0.700 |
Why?
|
Organoplatinum Compounds | 7 | 2019 | 407 | 0.680 |
Why?
|
Pancreatic Neoplasms | 11 | 2024 | 5367 | 0.660 |
Why?
|
Stomach Neoplasms | 5 | 2024 | 1453 | 0.610 |
Why?
|
Fluorouracil | 6 | 2019 | 1642 | 0.600 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2024 | 214 | 0.570 |
Why?
|
Camptothecin | 3 | 2017 | 591 | 0.540 |
Why?
|
Adenocarcinoma | 7 | 2024 | 6340 | 0.460 |
Why?
|
Colorectal Neoplasms | 9 | 2024 | 6925 | 0.410 |
Why?
|
Gallbladder Neoplasms | 3 | 2023 | 189 | 0.400 |
Why?
|
Antineoplastic Agents | 13 | 2023 | 13635 | 0.370 |
Why?
|
Antibodies, Monoclonal | 12 | 2023 | 9172 | 0.330 |
Why?
|
Esophageal Neoplasms | 4 | 2024 | 1653 | 0.320 |
Why?
|
Deoxycytidine | 7 | 2024 | 878 | 0.270 |
Why?
|
Bile Ducts, Intrahepatic | 3 | 2023 | 296 | 0.260 |
Why?
|
Dermatofibrosarcoma | 1 | 2006 | 48 | 0.260 |
Why?
|
Gastrointestinal Neoplasms | 4 | 2023 | 955 | 0.260 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2020 | 424 | 0.230 |
Why?
|
Carcinoma, Pancreatic Ductal | 3 | 2024 | 1727 | 0.230 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2812 | 0.220 |
Why?
|
Protein Kinase Inhibitors | 6 | 2023 | 5672 | 0.210 |
Why?
|
Phenylurea Compounds | 3 | 2021 | 529 | 0.210 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 86 | 0.200 |
Why?
|
Triazoles | 2 | 2020 | 903 | 0.200 |
Why?
|
Leucovorin | 3 | 2019 | 643 | 0.190 |
Why?
|
Biliary Tract | 1 | 2022 | 135 | 0.190 |
Why?
|
Esophagogastric Junction | 2 | 2024 | 347 | 0.190 |
Why?
|
Sirolimus | 4 | 2013 | 1533 | 0.180 |
Why?
|
Paclitaxel | 4 | 2024 | 1730 | 0.180 |
Why?
|
Carcinoid Tumor | 2 | 2013 | 224 | 0.180 |
Why?
|
Neutropenia | 2 | 2023 | 885 | 0.170 |
Why?
|
Anus Neoplasms | 1 | 2024 | 329 | 0.170 |
Why?
|
Gallstones | 1 | 2022 | 284 | 0.170 |
Why?
|
Cancer Care Facilities | 2 | 2014 | 421 | 0.170 |
Why?
|
ras Proteins | 3 | 2014 | 1054 | 0.160 |
Why?
|
Albumins | 2 | 2023 | 575 | 0.160 |
Why?
|
Rod Cell Outer Segment | 3 | 2001 | 51 | 0.160 |
Why?
|
Interleukin-1beta | 1 | 2024 | 998 | 0.160 |
Why?
|
Aged | 33 | 2024 | 169042 | 0.150 |
Why?
|
Pigment Epithelium of Eye | 3 | 2001 | 209 | 0.150 |
Why?
|
Neoplasm Metastasis | 6 | 2024 | 4910 | 0.150 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2425 | 0.140 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2553 | 0.140 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2020 | 1650 | 0.140 |
Why?
|
Neuroendocrine Tumors | 2 | 2013 | 641 | 0.130 |
Why?
|
Middle Aged | 33 | 2024 | 220584 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2014 | 3514 | 0.130 |
Why?
|
DNA Copy Number Variations | 1 | 2024 | 2020 | 0.120 |
Why?
|
Proto-Oncogene Proteins | 4 | 2014 | 4512 | 0.120 |
Why?
|
Aged, 80 and over | 16 | 2024 | 58894 | 0.120 |
Why?
|
Cholecalciferol | 1 | 2019 | 553 | 0.110 |
Why?
|
Anilides | 1 | 2017 | 411 | 0.110 |
Why?
|
Male | 36 | 2024 | 360358 | 0.110 |
Why?
|
Humans | 54 | 2024 | 760617 | 0.110 |
Why?
|
Pyridines | 2 | 2017 | 2874 | 0.110 |
Why?
|
Female | 37 | 2024 | 392148 | 0.110 |
Why?
|
Exercise Therapy | 1 | 2020 | 929 | 0.110 |
Why?
|
Glypicans | 1 | 2013 | 33 | 0.110 |
Why?
|
Metformin | 1 | 2020 | 906 | 0.100 |
Why?
|
Indoles | 2 | 2011 | 1830 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1611 | 0.100 |
Why?
|
beta Karyopherins | 1 | 2011 | 46 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 3 | 2014 | 1745 | 0.100 |
Why?
|
Adult | 24 | 2024 | 220969 | 0.090 |
Why?
|
Disease-Free Survival | 7 | 2017 | 6807 | 0.090 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2012 | 748 | 0.090 |
Why?
|
Vitamins | 1 | 2019 | 1635 | 0.090 |
Why?
|
Databases, Factual | 2 | 2018 | 7960 | 0.090 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 664 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 2 | 2010 | 2048 | 0.090 |
Why?
|
Quinazolines | 2 | 2013 | 1371 | 0.080 |
Why?
|
Catheter Ablation | 1 | 2021 | 2634 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2024 | 4020 | 0.080 |
Why?
|
Tubulin | 1 | 2011 | 692 | 0.070 |
Why?
|
Treatment Outcome | 13 | 2024 | 64568 | 0.070 |
Why?
|
Quinolines | 1 | 2013 | 764 | 0.070 |
Why?
|
Neoplasm Staging | 6 | 2024 | 11116 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2013 | 1626 | 0.070 |
Why?
|
Withholding Treatment | 1 | 2011 | 616 | 0.070 |
Why?
|
Photoreceptor Cells | 1 | 1987 | 235 | 0.070 |
Why?
|
Skin Neoplasms | 1 | 2006 | 5812 | 0.070 |
Why?
|
United States | 5 | 2020 | 72272 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2020 | 5304 | 0.070 |
Why?
|
Phagocytosis | 3 | 2001 | 1526 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2019 | 3411 | 0.070 |
Why?
|
Decision Making | 2 | 2017 | 3918 | 0.060 |
Why?
|
Retrospective Studies | 7 | 2024 | 80566 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 3730 | 0.060 |
Why?
|
Geriatric Assessment | 1 | 2013 | 1411 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 2057 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2018 | 546 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2020 | 8516 | 0.060 |
Why?
|
Retinal Degeneration | 2 | 2001 | 413 | 0.060 |
Why?
|
Cohort Studies | 4 | 2023 | 41457 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5697 | 0.060 |
Why?
|
Data Collection | 1 | 2013 | 3315 | 0.050 |
Why?
|
Estradiol | 1 | 2010 | 1937 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2018 | 4803 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1125 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 2 | 2018 | 558 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2014 | 6474 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1606 | 0.050 |
Why?
|
Chemokine CXCL12 | 2 | 2017 | 454 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2023 | 326 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 2008 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3868 | 0.050 |
Why?
|
Inflammation | 1 | 2020 | 10760 | 0.040 |
Why?
|
Survival Rate | 3 | 2020 | 12719 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 629 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4571 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2023 | 385 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 638 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2013 | 883 | 0.040 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 2650 | 0.040 |
Why?
|
Gadolinium DTPA | 1 | 2023 | 823 | 0.040 |
Why?
|
Gene Amplification | 1 | 2024 | 1087 | 0.040 |
Why?
|
Colonic Neoplasms | 1 | 2011 | 2533 | 0.040 |
Why?
|
Niacinamide | 1 | 2021 | 413 | 0.040 |
Why?
|
Edema | 1 | 2023 | 765 | 0.040 |
Why?
|
Mutation | 3 | 2024 | 30016 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2022 | 39063 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2913 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1700 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 610 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 808 | 0.040 |
Why?
|
Hyperbilirubinemia | 1 | 2017 | 74 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1779 | 0.030 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2017 | 145 | 0.030 |
Why?
|
Epistaxis | 1 | 2017 | 112 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1835 | 0.030 |
Why?
|
Intestinal Fistula | 1 | 2017 | 142 | 0.030 |
Why?
|
Angiopoietin-2 | 1 | 2017 | 172 | 0.030 |
Why?
|
Carbachol | 1 | 1996 | 223 | 0.030 |
Why?
|
Pancreas | 1 | 2022 | 1690 | 0.030 |
Why?
|
NF-kappa B | 1 | 2024 | 2481 | 0.030 |
Why?
|
Prognosis | 3 | 2020 | 29600 | 0.030 |
Why?
|
Intestinal Perforation | 1 | 2017 | 249 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2019 | 12334 | 0.030 |
Why?
|
Signal Transduction | 3 | 2013 | 23416 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2546 | 0.030 |
Why?
|
Cisplatin | 1 | 2020 | 1650 | 0.030 |
Why?
|
Prospective Studies | 3 | 2024 | 54360 | 0.030 |
Why?
|
Interleukin-6 | 2 | 2017 | 3206 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2023 | 6520 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6483 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2017 | 3492 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20988 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2023 | 2057 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2017 | 571 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 166 | 0.030 |
Why?
|
Administration, Oral | 2 | 2011 | 4010 | 0.020 |
Why?
|
Quality of Life | 2 | 2024 | 13347 | 0.020 |
Why?
|
Hydroxyestrones | 1 | 2010 | 17 | 0.020 |
Why?
|
Medical Oncology | 1 | 2023 | 2317 | 0.020 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 380 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10754 | 0.020 |
Why?
|
Somatostatin | 1 | 2012 | 447 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12447 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6305 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7196 | 0.020 |
Why?
|
Contrast Media | 1 | 2023 | 5305 | 0.020 |
Why?
|
Rats, Mutant Strains | 2 | 2001 | 60 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2191 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 129 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3822 | 0.020 |
Why?
|
Patient Dropouts | 1 | 2010 | 410 | 0.020 |
Why?
|
Survival Analysis | 2 | 2011 | 10073 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1386 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2023 | 14648 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 3085 | 0.020 |
Why?
|
Cycloheximide | 1 | 1987 | 343 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2014 | 10199 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5822 | 0.020 |
Why?
|
Proteins | 1 | 2001 | 6030 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81368 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1643 | 0.020 |
Why?
|
Rats, Inbred Strains | 1 | 1987 | 2088 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1297 | 0.020 |
Why?
|
Animals | 5 | 2024 | 168201 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12043 | 0.020 |
Why?
|
Vitamin D | 1 | 2019 | 3302 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 6224 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 22115 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 3077 | 0.010 |
Why?
|
Tumor Burden | 1 | 2010 | 1892 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 3599 | 0.010 |
Why?
|
Piperidines | 1 | 2012 | 1655 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2018 | 10432 | 0.010 |
Why?
|
Rats | 3 | 2001 | 23717 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 59179 | 0.010 |
Why?
|
Temperature | 1 | 1987 | 2223 | 0.010 |
Why?
|
Rats, Long-Evans | 1 | 2001 | 381 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3607 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2023 | 36402 | 0.010 |
Why?
|
Kinetics | 1 | 1987 | 6370 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2001 | 1545 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4174 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2008 | 2864 | 0.010 |
Why?
|
Time Factors | 2 | 2011 | 39913 | 0.010 |
Why?
|
Liver | 1 | 2014 | 7512 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2009 | 2218 | 0.010 |
Why?
|
Palliative Care | 1 | 2014 | 3592 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 1987 | 2802 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1996 | 18937 | 0.010 |
Why?
|
Hypertension | 1 | 2017 | 8529 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8542 | 0.010 |
Why?
|
Inositol 1,4,5-Trisphosphate | 1 | 1996 | 110 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3516 | 0.010 |
Why?
|
Lithium Chloride | 1 | 1996 | 82 | 0.010 |
Why?
|
Risk Factors | 1 | 2022 | 74115 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4570 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13495 | 0.010 |
Why?
|
Blotting, Western | 1 | 2001 | 5034 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2001 | 1662 | 0.010 |
Why?
|
Hospitalization | 1 | 2014 | 10704 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 88234 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20556 | 0.000 |
Why?
|
Calcium | 1 | 2001 | 5717 | 0.000 |
Why?
|
Risk Assessment | 1 | 2009 | 23972 | 0.000 |
Why?
|